Dr. Reddy Labs and Torrent Pharma - Quarterly Results
Dr. Reddy's Laboratories reported 11.72% growth in net sales at Rs.4,945 crore for the Jun-21 quarter. However, net profits were down -36% at Rs.380 crore on account of a Rs.184 crore asset impairment write-off in the Jun-21 quarter. Global generics sales were higher yoy but the API business was down. For Reddy Labs, the US accounts for 35% of revenues while India and other emerging markets account for 41%.
Dr. Reddy's Laboratories Quarterly Results
|
Rs in Crore |
Jun-21 |
Jun-20 |
YOY |
Mar-21 |
QOQ |
|
Total Income (Rs cr) |
₹ 4,945 |
₹ 4,427 |
11.72% |
₹ 4,768 |
3.71% |
|
Net Profit (Rs cr) |
₹ 380 |
₹ 595 |
-36.02% |
₹ 557 |
-31.74% |
|
Diluted EPS (Rs) |
₹ 22.89 |
₹ 35.78 |
₹ 33.51 |
||
|
Net Margins |
7.69% |
13.43% |
11.69% |
Gross margins at 52.2% was marginally lower than previous quarters. The positive feature of the quarter was R&D expenses at Rs.453 crore or 9.2% of revenues. For the Jun-21 quarter, the EBITDA margins stood at 20.7% while free cash flows (FCF) was at Rs.680 crore. Indian revenues were driven by COVID drug sales. Net margins for Jun-21 quarter stood at 7.69%; lower than 13.43% in Jun-20 quarter and 11.69% in Mar-21 quarter.
Among brokerages, Axis Securities, HDFC Securities and BNP Paribas have upgraded their price target while ICICI Securities had downgraded Reddy Labs to Hold.
Torrent Pharma Ltd reported 3.79% growth in net sales at Rs.2,134 crore for Jun-21 quarter. Net profit for the Jun-21 quarter was up 2.8% at Rs.330 crore on stable EBITDA margins and gross margins in the India business. During the quarter, Torrent Pharma launched anti-COVID drug, Bariticinib, which is currently under clinical trials for Molnupiravir. India revenues were up 18% at Rs.1,093 crore while the US sales were down -29% at Rs.266 crore. Due to price erosion. Germany grew 5%, Brazil 9% while CRAMS vertical grew 6% yoy.
Torrent Pharma Quarterly Results
|
Rs in Crore |
Jun-21 |
Jun-20 |
YOY |
Mar-21 |
QOQ |
|
Total Income (Rs cr) |
₹ 2,134 |
₹ 2,056 |
3.79% |
₹ 1,937 |
10.17% |
|
Net Profit (Rs cr) |
₹ 330 |
₹ 321 |
2.80% |
₹ 324 |
1.85% |
|
Diluted EPS (Rs) |
₹ 19.53 |
₹ 18.98 |
₹ 19.16 |
||
|
Net Margins |
15.46% |
15.61% |
16.73% |
Torrent Pharma reported gross margins of 72.4% and EBITDA margins of 34% in the Jun-21 quarter. Till June, Torrent Pharma had 54 ANDAs pending for approval with USFDA with 7 tentative approvals in place. Net margins were 15.46% for Jun-21 quarter compared to 15.61% in Jun-20 quarter and 16.73% in Mar-21 quarter.
Among brokerages, Motilal Oswal and ICICI Securities have upgraded their target for Torrent Pharma while BNP Paribas has downgraded its target.
Share Market Today
| Indices Name | Price | Price Change (% change) |
|---|---|---|
| S&P ASX 200 | 7581.50 | -101.5 (-1.32%) |
| CAC 40 | 8016.65 | 0 (0%) |
| DAX | 17917.28 | 0 (0%) |
| Dow Jones | 38085.80 | -375.12 (-0.98%) |
| FTSE 100 | 8078.86 | 2.26 (0.03%) |
| Hang Seng | 17708.88 | 424.34 (2.46%) |
| US Tech Composite | 15616.76 | -100.99 (-0.64%) |
| Nikkei 225 | 37934.69 | 306.21 (0.81%) |
| S&P 500 | 5048.42 | -23.21 (-0.46%) |
| Gift Nifty | 22626.50 | -46.5 (-0.21%) |
| Shanghai Composite | 3088.94 | 36.04 (1.18%) |
| Taiwan Weighted | 20120.51 | 263.09 (1.32%) |
| US 30 | 38180.20 | 55 (0.14%) |
Start Investing in 5 mins*
Rs. 20 Flat Per Order | 0% Brokerage
